Company news
Vor Biopharma Inc. news in 2022
Vor Biopharma Inc.'s news releases, calls and decks from 2022, newest first.
Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million
December 6, 2022
First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™
December 6, 2022
Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update
November 9, 2022
Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer
October 11, 2022
Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment
October 10, 2022
Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters
September 27, 2022
Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update
August 10, 2022
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA
June 9, 2022
Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update
May 11, 2022
Vor to Participate in Two Upcoming Investor Conferences
May 4, 2022
Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting
April 24, 2022
Vor Bio Announces Retirement of Chief Medical Officer
April 13, 2022
Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
March 13, 2022
Decks in 2022
- Technical Presentation (December 2022)
Technical · 35 slides · Dec 7, 2022